Charalambos (Babis) Andreadis, MD, MSCE

Charalambos (Babis) Andreadis, MD, MSCE

Associate Professor of Clinical Medicine, Department of Medicine, UCSF

Phone: (415) 353-2421 (appts)
Box 0324, UCSF
San Francisco, CA 94143-0324

UCSF Profiles | Physician Referral Directory

Cancer Center Membership

Program Member » Hematopoietic Malignancies» Developmental Therapeutics

Research Summary

I am an experienced hematologist in a comprehensive cancer center with clinical and research expertise in hematologic malignancies, autologous, and allogeneic blood and marrow transplantation. I have extensive clinical and research training in these areas and in genetic pharmacoepidemiology, in which I hold a Master’s degree. I have conducted and consulted on numerous clinical research endeavors in patients with hematologic malignancies, and I am currently the hematology clinical research co-chair at UCSF. I have collaborated with colleagues across departments and institutions (BMT-CTN and ALLIANCE) to conduct studies and perform data analysis on several aspects and phases of therapy for these patients. My personal area of interest involves the identification and characterization of genetic determinants of response to and toxicity from cancer therapy.


Oberlin College, Oberlin, OH, BA, 1993, Cum Laude, Biochemistry
College of Physicians & Surgeons, Columbia University, New York, NY, MD, 1998, Medicine
University of Pennsylvania, Philadelphia, PA, MSCE, 2005, Pharmacogenetics/Epidemiology

Professional Experience

  • 1998 - 2001
    Columbia-Presbyterian Medical Center (New York, NY), Resident, Department of Internal Medicine
  • 2001 - 2004
    Hospital of the University of Pennsylvania (Philadelphia, PA), Fellow, Division of Hematology/Oncology
  • 2004 - 2005
    University of Pennsylvania (Philadelphia, PA), Research Associate, Division of Hematology/Oncology
  • 2005 - 2006
    University of Pennsylvania (Philadelphia, PA), Clinical Instructor, Division of Hematology/Oncology
  • 2006 - 2008
    University of Pennsylvania (Philadelphia, PA), Assistant Professor, CE, Division of Hematology/Oncology
  • 2006 - 2008
    University of Pennsylvania (Philadelphia, PA), Associate Scholar, Center for Clinical Epidemiology and Biostatistics
  • 2008 - 2013
    Assistant Professor of Clinical Medicine, UCSF
  • 2013 - present
    Associate Professor of Clinical Medicine, UCSF

Honors & Awards

  • 1992
    Phi Beta Kappa, Z of Ohio
  • 1993
    Departmental honors and Cum Laude, Oberlin College
  • 1994 - 1998
    Nicholplus Interschool Fellowship, Columbia University
  • 1995
    McGraw-Hill Publishers Award, Columbia University
  • 1996
    Grove memorial Scholarship, Columbia University
  • 1997
    Alpha Omega Alpha, A of New York
  • 1998
    The Endocrine Society Medical Student Achievement Award
  • 2004
    Pharmacoepidemiology Training Award, University of Pennsylvania
  • 2012
    Hematology Teaching Award, Department of Medicine, UCSF
  • 2013
    Marc A. Shuman Mentoring Award, Division of Hematology/Oncology

Selected Publications

  • Thompson RQ, Patel HR, Andreadis C: Solid-phase determination of glucose in whole blood. Analytical Letters Vol. 27: 1201-14, 1994.
  • Zahedi R, Bissler JJ, Davis AE 3rd, Andreadis C, Wisnieski JJ: Unique C1 inhibitor dysfunction in a kindred without angioedema. II. Identification of an Ala443-->Val substitution and functional analysis of the recombinant mutant protein. Journal of Clinical Investigation 95(3): 1299-305, 1995.
  • Freda PU, Andreadis C, Khandji AG, Khoury M, Bruce JN, Jacobs TP, Wardlaw SL : Long-term treatment of prolactin-secreting macroadenomas with pergolide. Journal of Clinical Endocrinology and Metabolism Vol. 85: 8-13, 1999.
  • Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB: ATP citrate lyase is an important component of cell growth and transformation. Oncogene 24(41): 6314-22, 2005.
  • Chong EA, Svoboda J, Cherian S, Andreadis C, Downs LH, Zhuang H, Alavi A, Tsai DE, Schuster SJ: Regression of pulmonary MALT lymphoma after treatment with rituximab. Leukemia & Lymphoma 46(9): 1383-6, 2005.
  • Svoboda J, Andreadis C, Downs LH, Miller Jr WT, Tsai DE, Schuster SJ: Regression of advanced non-splenic marginal zone lymphoma after treatment of hepatitis C virus infection. Leukemia & Lymphoma 46(9): 1365-8, 2005.
  • Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, Thompson CB: ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8(4): 311-21, 2005.
  • Andreadis C, Schuster SJ, Chong EA, Svoboda J, Luger SM, Porter DL, Tsai DE, Nasta SD, Elstrom RL, Goldstein SC, Downs LH, Mangan PA, Cunningham KA, Hummel KA, Gimotty PA, Siegel DL, Glatstein E, Stadtmauer EA: Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma. Bone Marrow Transplantation 36(11): 955-61, 2005.
  • Fuster D, Chiang S, Andreadis C, Guan L, Zhuang H, Schuster S, Alavi A: Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma? Nuclear Medicine Communications 27(1): 11-5, 2006.
  • Elstrom RL, Andreadis C, Aqui NA, Ahya VN, Bloom RD, Brozena SC, Olthoff KM, Schuster SJ, Nasta SD, Stadtmauer EA, and Tsai DE: Treatment of PTLD with Rituximab or Chemotherapy: The University of Pennsylvania Experience. American Journal of Transplantation 6(3): 569-76, 2006.
  • Svoboda J, Andreadis C, Elstrom R, Chong EA, Downs LH, Berkowitz A, Luger S, Porter D, Nasta SD, Tsai D, Loren A, Siegel DL, Glatstein E, Alavi A, Stadtmauer E, Schuster S: Prognostic Value of FDG-PET Imaging in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation Bone Marrow Transplantation 38(3): 211-6, 2006.
  • Frey NV, Svoboda J, Andreadis C, Tsai DE, Schuster SJ, Elstrom R, Rubin SC, Nasta SD : Primary lymphomas of the cervix and uterus: the University of Pennsylvania experience and a review of the literature. Leukemia & Lymphoma 47(9): 1894-901, 2006.
  • Tsai DE, Luger SM, Kemner A, Swider C, Goradia A, Tomczak E, DiPatri E, Bagg A, Nowell P, Loren AW, Perl A, Schuster S, Thompson JE, Porter D, Andreadis C, Stadtmauer EA, Goldstein S, Ghalie R, Carroll M: Evidence of Myeloid Differentiation in Non-M3 Acute Myeloid Leukemia Treated with the Retinoid X Receptor Agonist Bexarotene. Cancer Biology & Therapy 6(1):18-21, 2007.
  • Andreadis C, Gimotty PA, Wahl P, Hammond R, Houldsworth J, Schuster SJ, Rebbeck TR : Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma. Blood. 109(8): 3409-3416, 2007.
  • Ahya VN, Douglas LP, Andreadis C, Arnoldi S, Svoboda J, Kotloff RM, Hadjiliadis D, Sager JS, Woo YJ, Pochettino A, Schuster SJ, Stadtmauer EA, Tsai DE.: Association between elevated whole blood Epstein-Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft rejection. Journal of Heart Lung Transplant 26(8): 839-44, 2007.
  • Vogl DT, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Perl A, Loren AW, Goldstein SC, Nasta SD, Andreadis C, Mangan PA, Hummel K, Siegel DL, Glatstein E, Stadtmauer EA: Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support. American Journal of Hematology. 82(12):1071-5, 2007
  • Mato AR, Morgans AK, Roullet MR, Bagg A, Glatstein E, Litt HI, Downs LH, Chong EA, Olson ER, Andreadis C, Schuster SJ. Primary Cardiac Lymphoma: Utility of Multimodality Imaging in Diagnosis and Management. Cancer Biology & Therapy. 6(12) [Epub ahead of print], 2007
  • Tsai DE, Douglas L, Andreadis C, Vogl DT, Arnoldi S, Kotloff R, Svoboda J, Bloom RD, Olthoff KM, Brozena SC, Schuster SJ, Stadtmauer EA, Robertson ES, Wasik MA, Ahya VN. EBV PCR in the Diagnosis and Monitoring of Posttransplant Lymphoproliferative Disorder: Results of a Two-Arm Prospective Trial. American Journal Transplant. 2008 Feb 29; [Epub ahead of print]
  • Review Articles and Chapters:
  • Andreadis C, Luger S, Stadtmauer E: Anti-CD33 calicheamicin immunoconjugate therapy of acute myeloid leukemia Cytotoxins and Immunotoxins for Cancer Therapy: Clinical Applications Kawakami K, Aggarwal BB, Puri RK. (eds.). CRC Press, July 2004.
  • Hatzivassiliou G, Andreadis C, and Thompson CB: Akt-directed metabolic effects in cancer. Drug Discovery Today: Disease Mechanisms Vol. 2: 255-62, 2005.